Real-World Experience Using Bimekizumab for the Treatment of Moderate-to-Severe Psoriasis From a Single Outpatient Dermatology Clinic

被引：3
|
作者：
Cirone, Katrina D. [1 ]
Lovegrove, Fiona E. [1 ,2 ,3 ]
机构：
[1] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[2] Lovegrove Dermatol, London, ON, Canada
[3] Lovegrove Dermatol, 207-140 Oxford St East, London, ON, Canada
来源：
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY | 2024年 / 28卷 / 01期
关键词：
bimekizumab; psoriasis; biological therapy; real-world data; systemic therapy; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; MULTICENTER; EFFICACY; SAFETY;
D O I：
10.1177/12034754231217205
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：78 / 79
页数：2
相关论文
共 50 条
  • [21] Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience
    Gonulal, Melis
    Altunay, Ilknur Kivanc
    Dogan, Sinan
    Turkmen, Meltem
    Balci, Didem Didar
    Ozturkcan, Serap
    DERMATOLOGIC THERAPY, 2022, 35 (12)
  • [22] Evaluating risankizumab for moderate-to-severe plaque psoriasis: real-world outcomes from an international study
    Bagit, Ahmed
    Maliyar, Khalad
    Mansour, Mark
    Georgakopoulos, Jorge
    Rankin, Brian
    Lytvyn, Yuliya
    Zaaroura, Hiba
    Park, Ye-Jean
    Wang, Emilie
    Mufti, Asfandyar
    Torres, Tiago
    Le, Ana Maria
    Vender, Ronald
    Prajapati, Vimal H.
    Yeung, Jensen
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [23] BUDGET IMPACT ANALYSIS OF BIMEKIZUMAB FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN GREECE
    Koulentaki, M.
    Tzanetakos, C.
    Stratigos, A.
    Sotiriou, E.
    Ladha, I
    Kountouris, V
    Relakis, J.
    Kourlaba, G.
    VALUE IN HEALTH, 2022, 25 (12) : S185 - S185
  • [24] A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
    Emily K. Haque
    Aaminah Azhar
    John Corbett
    Jillian Frieder
    Xuan Wang
    Alan Menter
    Dermatology and Therapy, 2020, 10 : 1121 - 1135
  • [25] Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study
    Torres, Tiago
    Varela, Paulo
    Bastos, Pedro Mendes
    Magina, Sofia
    Henrique, Martinha
    Ferreira, Paulo
    DRUGS IN CONTEXT, 2024, 13
  • [26] A Real-World Evaluation of the Long-Term Safety and Efficacy of Infliximab in the Treatment Moderate-to-Severe Psoriasis
    Haque, Emily K.
    Azhar, Aaminah
    Corbett, John
    Frieder, Jillian
    Wang, Xuan
    Menter, Alan
    DERMATOLOGY AND THERAPY, 2020, 10 (05) : 1121 - 1135
  • [27] Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
    Jung, Seung-Won
    Lim, Sung Ha
    Jeon, Jae Joon
    Heo, Yeon-Woo
    Choi, Mi Soo
    Hong, Seung-Phil
    BIOMEDICINES, 2022, 10 (05)
  • [28] Clinical challenges faced in real-world management of moderate-to-severe psoriasis: a personal view
    Cerio, Rino
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2017, 152 (06): : 551 - 554
  • [29] Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis
    Papadavid, E.
    Rompoti, N.
    Theodoropoulos, K.
    Kokkalis, G.
    Rigopoulos, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (07) : 1173 - 1179
  • [30] Efficacy of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Real-World Practice in a Single Center
    Bai, Juan
    Su, Wang
    Fang, Hong
    Qiao, Jianjun
    AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (03) : e332 - e334
12345